3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
4
Breast Neoplasms
3
Thyroid Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Renal Cell
2
Carcinoma, Medullary
2
Thyroid cancer, medullary
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Prostatic Neoplasms
1
Pleural Effusion
1
Peritoneal Neoplasms
1
Neuroblastoma
1
Mesothelioma
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Adenocarcinoma, Follicular
1
Adenocarcinoma Of Esophagus
1
Interventions
Docetaxel
56
Prednisone
36
enzalutamide
25
Leuprolide
24
Magnetic Resonance Spectroscopy
19
Abiraterone Acetate
19
bicalutamide
17
Radiotherapy
15
Goserelin
15
abiraterone
12
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
11
olaparib
9
Androgen Antagonists
9
gallium 68 PSMA-11
8
cabazitaxel
8
Radiotherapy, Intensity-Modulated
8
Metformin
8
Ketoconazole
8
Gonadotropin-Releasing Hormone
8
Cyclophosphamide
8
apalutamide
7
Doxorubicin
7
luprolide acetate gel depot
6
cabozantinib
6
Radiosurgery
6
Estramustine
6
Dexamethasone
6
Calcitriol
6
Biopsy
6
pembrolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Prostatic Neoplasms
×
vandetanib
×
Clear all
NCT00686036
2016-12-21
ZENITH
Sanofi
Phase 2
Terminated
17 enrolled
4 charts